Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971788 | 0.88 | MAPT (0.38) | MAPTMAPK1PNMTTAAR1PPARG | |
| SCHEMBL2172166 | 0.83 | PIK3CA (0.45) | MAPTPNMTTAAR1IDO1ALDH1A1 | |
| SCHEMBL1568015 | 0.82 | PNMT (0.41) | MAPTMAPK1PNMTTAAR1PPARG | |
| SCHEMBL21741993 | 0.82 | XDH (0.47) | MAPTMAPK1PNMTTAAR1PPARG | |
| SCHEMBL27461393 | 0.82 | MAPT (0.38) | MAPTMAPK1PNMTTAAR1PPARG | |
| SCHEMBL1780435 | 0.80 | IDO1 (0.54) | PNMTTAAR1IDO1ALDH1A1SIGMAR1 | |
| SCHEMBL896163 | 0.80 | HTT (0.42) | ALDH1A1 | |
| SCHEMBL28920633 | 0.80 | PPARG (0.38) | MAPTMAPK1PPARGPPARAGRM2 | |
| SCHEMBL2092845 | 0.78 | MAPT (0.41) | MAPTMAPK1PNMTTAAR1PPARG | |
| SCHEMBL2098325 | 0.78 | MAPT (0.41) | MAPTMAPK1PNMTTAAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452251-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023122494-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022200162-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACECION PHARMA APS (DK) | 2022-09-29 | — | — | WO | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3749649-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| EP-3704096-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2054410-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | Wyeth (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2030982-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008021331-A2 | OXAZOLIDONE DERIVATIVES AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1697322-A4 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CYCLOPENTANOINDOLE DERIVATIVES | MERCK FROSST CANADA LTD (CA) | 2007-12-26 | — | — | EP | disclosed |
| EP-1697322-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CYCLOPENTANOINDOLE DERIVATIVES | Merck Frosst Canada Ltd. (CA) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005056527-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CYCLOPENTANOINDOLE DERIVATIVES | MERCK FROSST CANADA LTD. (CA) | 2005-06-23 | — | — | WO | disclosed |
| US-6579577-B2 | High voltage holding ratio which has a very small degree of temperature dependence, a low threshold voltage | CHISSO CORPORATION (JP) | 2003-06-17 | — | — | US | disclosed |
| US-20020166994-A1 | Substituted benzene derivative, liquid crystal composition, and liquid crystal display element | CHISSO CORPORATION (JP) | 2002-11-14 | — | — | US | disclosed |
| CN-1237952-A | Substituted benzene derivative, liquid-crystal composition, and liquid-crystal display element | CHISSO CORP (JP) | 1999-12-08 | — | — | CN | disclosed |
| EP-0934919-A1 | SUBSTITUTED BENZENE DERIVATIVE, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT | CHISSO CORPORATION (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | MAPT 927/4885MAPK1 1113/4885PNMT 1591/4885 |
| US-20020166994-A1 | Substituted benzene derivative, liquid crystal composition, and liquid crystal display element | OCIAD2, OCIAD1, POU2F1 | MAPT 2985/4885MAPK1 998/4885PNMT 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.